Skip to main content
SpringerLink
Log in

Family History of Breast and Ovarian Cancer and the Risk of Breast Carcinoma in situ

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

A family history of breast cancer is an important risk factor for breast carcinoma in situ (BCIS), however, there are no detailed analyses of its variation in effect by number, type, laterality or age at onset of affected relatives nor by association with ovarian cancer. In addition, the role of the breast cancer susceptibility genes, BRCA1 and BRCA2, in the development of BCIS is unclear.

Objective. To better define the role of: (1) a family history of breast and ovarian cancer and (2) the cancer susceptibility genes, BRCA1 and BRCA2, in the development of BCIS.

Methods. The data are 875 ductal carcinoma in situ (DCIS) and 123 lobular carcinoma in situ (LCIS) cases diagnosed among residents of the state of Connecticut from September 15, 1994 to March 14, 1998 and between the age of 20 and 79 years. Controls (n = 999) are female Connecticut residents collected via random-digit-dial and frequency matched to the cases by 5-year age intervals. Telephone interviews were used to collect information on risk factors and cancer screening history.

Logistic regression was used to provide maximum likelihood estimates of the odds ratios (OR) with 95% confidence intervals (95% CI). The probability of being a BRCA1 and/or BRCA2 gene carrier was calculated for each case and control, using family history of breast and ovarian cancer, age/age at diagnosis for relatives, prevalence and penetrance data for BRCA1/BRCA2, and self-report of Jewish heritage.

Results. Cases with DCIS or LCIS were significantly more likely to report a first degree family history of breast cancer (OR: 1.6, 95% CI: 1.3, 2.1 and 1.8, 95% CI: 1.2, 2.9, respectively) than were controls. In addition, DCIS cases were 2.4 (95% CI: 0.8, 7.2) times more likely than controls to report both an affected mother and sister. An inverse association was suggested between age at onset and DCIS risk with cases aged 49 years or younger at 2.1 (95% CI: 1.3, 3.4) times the risk of controls (95% CI) versus 1.5 (95% CI: 1.1, 2.0) for cases older than 49 years. An elevated risk of DCIS was associated with a family history of ovarian cancer but did not reach statistical significance (OR: 1.3, 95% CI: 0.7, 2.5). Approximately 3.7% and 1.9% of DCIS cases were predicted to carry a mutation in BRCA1 and BRCA2, respectively.

Conclusions. A family history of breast cancer is associated with an increased risk of DCIS and LCIS, particularly among women with multiple relatives affected at early ages. Statistical risk models predict a low prevalence rate of BRCA1 and BRCA2 in DCIS; these estimates await confirmation through laboratory testing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Claus EB, Risch N, Thompson WD: Age at onset as an indicator of familial risk of breast cancer J Epidemiol 131: 961-972, 1990

    Google Scholar 

  2. Lynch HT, Watson P, Conway T, Fitzsimmons SL, Lynch J: Breast cancer family history as a risk factor for early onset breast cancer. Br Cancer Res Treat 11: 263-267, 1988

    Google Scholar 

  3. Ottman R, Pike MC, King MC, Casagrande JT, Henderson BE: Familial breast cancer in a population based series. Am J Epidemiol 123: 15-21, 1986

    Google Scholar 

  4. Sattin RW, Rubin GL, Webster LA, Huezo CM, Wingo PA, Ory HW, Layde PM: The Cancer and Steroid Hormone Study: Family history and risk of breast cancer. JAMA 253: 1908-1913, 1985

    Google Scholar 

  5. Schwartz AG, King MC, Belle SH, Satariano WA, Swanson GM: Risk of breast cancer to relatives of young breast cancer patients. J Nat Cancer Inst 75: 665-668, 1985

    Google Scholar 

  6. Kelsey JL, Gammon MD: Epidemiology of breast cancer. Am J Epidemiol 12: 228-240, 1990

    Google Scholar 

  7. Slattery ML, Kerber RA: A comprehensive evaluation of family history and breast cancer risk: the Utah Population Database JAMA 270: 1563-1568, 1994

    Google Scholar 

  8. Colditz GA, Willett WC, Hunter DJ, Stampfer MJ, Manson JE, Hennekens CH, Rosner BA: Family history, age, and risk of breast cancer. JAMA 270: 338-343, 1548, 1993

    Google Scholar 

  9. Claus EB, Risch N, Thompson WD: Genetic analysis of breast cancer in the Cancer and Steroid Hormone Study. Am J Hum Genet 48: 232-242, 1991

    Google Scholar 

  10. Weiss HA, Brinton LA, Brogan D, Coates RJ, Gammon MD, Malone KE, Schoenberg JB, Swanson CA: Epidemiology of in situ and invasive breast cancer in women aged under 45. Br J Cancer 73(10): 1298-1305, 1996

    Google Scholar 

  11. Longnecker MP, Bernstein L, Paganini-Hill A, Enger SM, Ross RK: Risk factors for in situ breast cancer. Cancer Epidemiol Biomarkers Prev 5: 961-965, 1996

    Google Scholar 

  12. Brinton LA, Hoover R, Fraumini JrJF: Epidemiology of minimal breast cancer. JAMA 249: 483-487, 1983

    Google Scholar 

  13. Kerlikowske K, Barclay J, Grady D, Sickles EA, Ernster V: Comparison of risk factors for ductal carcinoma in situ and invasive breast cancer. JNCI 89: 77-82, 1997

    Google Scholar 

  14. Newcomb P, Storer BE, Marcus PM: Risk factors for carcinoma in situ of the breast. Abstract, American Society of Preventive Oncology, Bethesda, MD, 1994

    Google Scholar 

  15. Claus EB, Stowe M, Holford T, Carter D: The genetic epidemiology of breast carcinoma in situ. US Army Medical Research and Material Command's 1997 Meeting-DOD Breast Cancer Research Program: An Era of Hope, 1997 Proceedings. Washington, DC

  16. Claus EB, Risch NR, Thompson WD, Carter D: Relationship between breast histopathology and family history of breast cancer. Cancer 71: 147-153, 1993

    Google Scholar 

  17. Claus EB, Stowe M, Carter D: Breast carcinoma in situ: Risk factors and screening patterns. J Nat Cancer Inst 93: 1811-1817, 2001

    Google Scholar 

  18. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71, 1994

    Google Scholar 

  19. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D: Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265: 2088-2090, 1994

    Google Scholar 

  20. Colditz GA, Manson JE, Hankinson SE: The Nurses' Health Study: 20-year contribution to the understanding of health among women. J Womens Health 6: 49-62, 1997

    Google Scholar 

  21. SAS Institute Inc.: SAS/STAT User's Guide, Version 6. 4th edn, Vol 1, SAS Institute Inc., Cary, NC, 1989

  22. Euhus D, Berry D, Parmigiani G, Iversen E, Frawley W: Cancer gene with BRCAPRO. University of Texas, 1998

  23. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E: Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Nat Cancer Inst 89: 227-238, 1997

    Google Scholar 

  24. Parmigiani G, Berry DA, Aguilar O: Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62: 145-158, 1998

    Google Scholar 

  25. Ford D, Easton DF, Peto J: Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57: 1457-1462, 1995

    Google Scholar 

  26. Easton D, Ford D, Bishop DT: The Breast Cancer Linkage Consortium: Breast and ovarian cancer incidence in BRCA1 mutation carriers. Am J Hum Genet 56: 265-271, 1995

    Google Scholar 

  27. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401-1408, 1997

    Google Scholar 

  28. Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G: Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. JNCI 94: 844-851, 2002

    Google Scholar 

  29. Statement of the American Society of Clinical Oncology: Genetic testing for cancer susceptibility. Indications for genetic testing. Table 3 (Acessed July 3, 2002). available at: http://www.asco.org/prof/pp/html/m_ppgenetc.htm#tab3

  30. Schildkraut JM: Family history of cancer as a risk factor for epithelial carcinoma of the ovary. PhD Dissertation, Yale University Press, 1987

  31. Myriad Genetics (Acessed July 3, 2002). Available at: http://www.myriad.com/med/brac/mutptables.html

  32. Shattuck-Eidens D, McClure M, Simard J, Labrie F, Narod S, Couch F, Hoskins K, Weber B, Castilla, Erdos M: A Family history of breast and ovarian cancer 15 collaborative study of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA 273: 535-541, 1995

    Google Scholar 

  33. Langston AA, Malone KE, Thompson JD, Daling JR, Ostrander EA: BRCA1 mutations in a population-based sample of young women with breast cancer. N Engl J Med 334: 137-142, 1996

    Google Scholar 

  34. Fitzgerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, Silva-Arrieto S, Finkelstein DM, Beer-Romero P, Englert C, Sgroi DC, Smith BL, Younger JW, Garber JE, Duda RB, Mayzel KA, Isselbacher KJ, Friend SH, Haber DA: Germline BRCA1 mutations in Jewish and non-Jewish women with early onset breast cancer. N Engl J Med 334: 143-149, 1996

    Google Scholar 

  35. Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC: The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11: 198-200, 1995

    Google Scholar 

  36. Roa BB, Boyd AA, Volcik K, Richards CS: Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14: 185-187, 1996

    Google Scholar 

  37. Oddoux C, Struewing JP, Clayton CM, Neuhausen S, Brody LC, Kaback, Haas B, Norton L, Borgen P, Jhanwar S, Goldgar D, Ostrer H, Offit K: The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet 14: 188-190, 1996

    Google Scholar 

  38. Neuhausen S, Gilewski T, Norton L, Tran T, McGuire P, Swensen J, Hampel H, Borgen P, Brown K, Skolnick M, Shattuck-Eidens D, Jhanwar S, Goldgar D, Offit K: Recurrent BRCA2 617delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet 13: 126-128, 1996

    Google Scholar 

  39. Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC: Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279: 915-921, 1998

    Google Scholar 

  40. Malone KE, Daling JR, Thompson JD, O'Brien CA, Francisco LV, Ostrander EA: BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. JAMA 279: 922-929, 1998

    Google Scholar 

  41. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL: BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336: 1409-1415, 1997

    Google Scholar 

  42. Krainer M, Silva-Arrieta S, Fitzgerald MG, Shimada A, Ishioka C, Kanamaru R, MacDonald DJ, Unsal H, Finkelstein DM, Bowcock A, Isselbacher KJ, Haber DA: Differential contributions of BRCA1 and BRCA2 to early onset breast cancer. N Engl J Med 336: 1416-1421, 1997

    Google Scholar 

  43. Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A: Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early onset breast cancer. J Nat Cancer Inst 93: 1215-1223, 2001

    Google Scholar 

  44. Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early onset breast cancer. J Nat Cancer Inst 91: 943-949, 1999

    Google Scholar 

  45. Szabo CI, King MC: Population genetics of BRCA1 and BRCA2. Am J Hum Genet 60: 1013-1020, 1997

    Google Scholar 

  46. Syrjakoski K, Vahteristo P, Eerola H, Tamminen A, Kivinummi K, Sarantaus L, Holli K, Blomqvist C, Kallioniemi OP, Kainu T, Nevanlinna H: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients. J Nat Cancer Inst 92: 1529-1531, 2001

    Google Scholar 

  47. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, Linder-Stephenson L, Salerno G, Conway TA, Lynch HT: Hereditary breast cancer. Pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 77: 697-709

Download references

Author information

Authors and Affiliations

  1. Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, USA

    Elizabeth B. Claus & Meredith Stowe

  2. Department of Pathology, Yale University School of Medicine, New Haven, CT, USA

    Darryl Carter

Authors
  1. Elizabeth B. Claus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Meredith Stowe
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Darryl Carter
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Claus, E.B., Stowe, M. & Carter, D. Family History of Breast and Ovarian Cancer and the Risk of Breast Carcinoma in situ . Breast Cancer Res Treat 78, 7–15 (2003). https://doi.org/10.1023/A:1022147920262

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022147920262

Search

Navigation